HDAC inhibitors in HIV

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 47-54

  Wightman, Fiona ^a,b   Ellenberg, Paula ^a,b   Churchill, Melissa ^b   Lewin, Sharon R ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

cure; HDAC inhibitor; HIV; latency; transcription

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; BELINOSTAT; BRYOSTATIN; BUTYRIC ACID; ENFUVIRTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; PANOBINOSTAT; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; ARTHRITIS; BINDING SITE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME ACTIVATION; FATIGUE; FOLLOW UP; GENE ACTIVATION; GENE REPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC JUVENILE ARTHRITIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; LONG TERMINAL REPEAT; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; VIRUS LATENCY;

EID: 84855419002     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.95     Document Type: Review

References (103)

1. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ Tcells. Nat Med 2003; 9: 727-728. (Pubitemid 36749221)
2. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798-812.
3. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-222.
4. Colin L, Van Lint C. Molecularcontrol of HIV-1 postintegration latency: implicationsfor the development of new therapeutic strategies. Retrovirology 2009; 6: 111.
5. Lewin SR, Murray JM, Solomon A, Wightman F, Cameron PU, Purcell DJ et al.Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. JAcquir Immune Defic Syndr 2008; 47: 140-147. (Pubitemid 351172180)
6. Coiras M, Lopez-Huertas MR, Sanchez del Cojo M, Mateos E, Alcami J. Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. AIDSRev 2010; 12: 103-112.
7. Robertson JM, Mac Leod M, Marsden VS, Kappler JW, Marrack P. Notall CD4+ memory Tcells are long lived. Immunol Rev 2006; 211: 49-57. (Pubitemid 43882960)
8. Easley R, Van Duyne R, Coley W, Guendel I, Dadgar S, Kehn-Hall K et al. Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim Biophys Acta 2010;1799: 275-285.
9. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappa B p50 promotes HIV latencythrough HDAC recruitmentand repressionof transcriptional initiation. Embo J 2006; 25: 139-149. (Pubitemid 43077303)
10. Duverger A, Jones J, May J, Bibollet-Ruche F,Wagner FA, Cron RQet al. Determinants of HIV-1 latencyestablishment. J Virol 2009, 3078-3093.
11. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39: 63-74. (Pubitemid 47446257)
12. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H et al. Cellular micro RNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241-1247. (Pubitemid 47530631)
13. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirsand latencymodels. Virology 2011; 411: 344-354.
14. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat Proc Natl Acad Sci USA 1989; 86: 5974-5978. (Pubitemid 19217570)
15. Folks TM,Justement J, Kinter A, Dinarello CA, Fauci AS.Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-802.
16. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of Tcells in vitro. Embo J 2003; 22: 1868-1877. (Pubitemid 36460143)
17. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76: 8776-8786. (Pubitemid 34864073)
18. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86: 2365-2368. (Pubitemid 19102509)
19. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009; 23: 1461-1471.
20. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-13197. (Pubitemid 27518498)
21. Dokmanovic M, Marks PA. Prospects: histonedeacetylase inhibitors. J Cell Biochem 2005; 96: 293-304.
22. Bosque A, Planelles V Induction of HIV-1 latency and reactivation in primary memory CD4+Tcells. Blood 2009; 113: 58-65.
23. Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 2008; 181: 7713-7720.
24. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84: 5958-5974.
25. Swiggard WJ, O'Doherty U, Mc Gain D, Jeyakumar D, Malim MH. Long HIV type 1 reversetranscripts can accumulatestably within resting CD4+ Tcellswhileshortones are degraded. AIDS Res Hum Retroviruses 2004; 20: 285-295. (Pubitemid 38429401)
26. Burke B, Brown HJ, Marsden MD, Bristol G, Vatakis DN, Zack JA. Primary cell model for activation-inducible human immunodeficiency virus. J Virol 2007; 81: 7424-7434. (Pubitemid 47047831)
27. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci USA 2010; 107: 16934-16939.
28. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ Tcells to HIV-1 infection: A novel model of HIV-1 latency. Blood 2007; 110: 4161-4164. (Pubitemid 351377777)
29. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-3486.
30. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25: 207-212.
31. Contreras X, Schweneker M, Chen CS, Mc Cune JM, Deeks SG, Martin J et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284: 6782-6789.
32. Barboric M, Peterlin BM. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLo S Biol 2005; 3: e76.
33. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009; 83: 4749-4756.
34. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74: 6790-6799. (Pubitemid 30470662)
35. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency byrecruiting histonedeacetylase 1 to the human immunodeficiencyvirustype 1 promoter. J Virol 2007; 81: 10914-10923. (Pubitemid 47536066)
36. Verdin E, Paras Jr P, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12: 3249-3259. (Pubitemid 23232756)
37. Roth SY, Denu JM, Allis CD. Histone acetyl transferases. Annu Rev Biochem 2001; 70: 81-120.
38. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749. (Pubitemid 36399066)
39. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 1997; 71: 6113-6127. (Pubitemid 27304953)
40. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in responseto histoneacetylation. EMBOJ 1996; 15:1112-1120. (Pubitemid 26077840)
41. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
42. Romerio F, Gabriel MN, Margolis DM. Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 1997; 71: 9375-9382. (Pubitemid 27492380)
43. Tyagi M, Karn J.CBF-1 promotestranscriptional silencingduringtheestablishment of HIV-1 latency. Embo J 2007; 26: 4985-4995. (Pubitemid 350261291)
44. Malcolm T, Chen J, Chang C, Sadowski I. Induction ofchromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling. Virus Genes 2007; 35: 215-223. (Pubitemid 47087561)
45. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificityand reactivation of HIVtype 1 (HIV-1) from latently infected cells. J Biol Chem 2011; 286: 22211-22218.
46. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J 2007; 26: 412-423. (Pubitemid 46160942)
47. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-1806.
48. Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54: 1-9.
49. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLo S One 2010; 5: e9390.
50. Valenzuela-Fernandez A, Alvarez S, Gordon-Alonso M, Barrero M, Ursa A, Cabrero JR et al. Histonedeacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell 2005; 16: 5445-5454. (Pubitemid 41566852)
51. Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, Saleh S et al. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 2009; 23: 2047-2050.
52. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D et al. Shock and kill effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6: 52.
53. Ying H, Zhang Y, Lin S, Han Y, Zhu HZ. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int JMol Med 2010; 26: 265-272.
54. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005; 366: 549-555. (Pubitemid 41140329)
55. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A et al. Valproic acidwithout intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ Tcells. AIDS 2008; 22: 1131-1135.
56. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22: 1125-1129.
57. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195: 833-836. (Pubitemid 46363928)
58. Steel A, Clark S, Teo I, Shaunak S, Nelson M, Gazzard B et al. No change to HIV-1 latencywithvalproatetherapy. AIDS 2006; 20: 1681-1682.
59. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot J-Sp, Quivy V et al. Synergistic activation of HIV-1 expression bydeacetylase inhibitors and prostratin: implications for treatment of latent infection. PLo S ONE 2009; 4: e6093.
60. Liu Y, Denlinger CE, Rundall BK, Smith PW, Jones DR. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of Rel A/p65. J Biol Chem 2006; 281: 31359-31368. (Pubitemid 46041400)
61. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011; 17: 466-472.
62. Wightman F RS, Ramanayake S, Saleh S, Solomon A, Dear A, Xhilaga M et al. Potency and Toxicityof HDACi and Other Immune Activators in Inducing HIV Production Using a Primary Resting T-cell Model of HIVLatency [abstract 198], Poster presented at the 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, 2011.
63. Xhilaga M. The novel HDAC inhibitors metacept (MCT)-1 and MCT-3 have potent activityon HIV-1 transcription in latently infected cells. AIDS 2009; 23: 2047-2050.
64. Lin S, Zhang Y, Ying H, Zhu H. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells. Curr HIV Res 2011; 9: 202-208.
65. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett 2011; 585: 1103-1111.
66. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodefi-ciency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 2004; 78: 10507-10515. (Pubitemid 39258376)
67. Wender PA, Kee JM, Warrington JM. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 2008; 320: 649-652. (Pubitemid 351928343)
68. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Munoz-Fernandez MA et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8: 418-429.
69. Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLo S One 2011; 6: e18270.
70. Vigna E, Recchia AG, Madeo A, Gentile M, Bossio S, Mazzone C et al. Epigenetic regulation in myelodysplastic syndromes: implications for therapy. Expert Opin Investig Drugs 2011; 20: 465-493.
71. Fernandez G, Zeichner SL. Cell line-dependentvariability in HIVactivation employing DNMT inhibitors. Virol J 2010; 7: 266.
72. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global Tcell activation. JVirol 2011; 85: 6060-6064.
73. Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD et al. High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 2011; 286: 21083-21091.
74. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76. (Pubitemid 40215840)
75. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002; 277: 2073-2080. (Pubitemid 34968790)
76. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targetsresponsiblefortheiranti-cancereffect. Invest New Drugs 2010; 28(Suppl 1): S3-20.
77. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ et al.Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphomacell lines. Blood 2008; 112: 1424-1433.
78. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-1130. (Pubitemid 46220659)
79. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96: 3847-3856.
80. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC func-tions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118: 2562-2573. (Pubitemid 351949783)
81. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, van Beekum O et al. Regulation of Tregfunctionality byacetylation-mediated Foxp3 protein stabiliza-tion. Blood 2010; 115: 965-974.
82. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 2011; 5: 171-186.
83. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. JAcquir Immune Defic Syndr 2007; 46: 72-77. (Pubitemid 47514615)
84. Ellis L, Pan Y, Smyth GK, George DJ, Mc Cormack C, Williams-Truax R et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-4510.
85. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastro-intestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010; 11: 459-464.
86. Kim SY, Woo MS, Kim WK, Choi EC, Henson JW, Kim HS. Glial cell-specific regulation of the JC virus early promoter by histone deacetylase inhibitors. J Virol 2003; 77: 3394-3401. (Pubitemid 36297258)
87. Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF et al. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther 2010; 17: 203-211.
88. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus ccc DNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837. (Pubitemid 43374531)
89. Jones K, Nourse J, Corbett G, Gandhi MK. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Int JLab Hematol 2010; 32: e169-e174.
90. Prince HM, Bishton MJ, Harrison SJ. Clinical studiesof histonedeacetylase inhibitors. Clin Cancer Res 2009; 15: 3958-3969.
91. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES et al. Reactivation of DNA viruses in association with histonedeacetylase inhibitortherapy: A caseseries report. Haematologica 2009; 94: 1618-1622.
92. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, Mc Arthur JC, Brew BJ et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-asso-ciated dementia. Ann Neurol 2009; 66: 253-258.
93. Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 2000; 879: 42-49.
94. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neurosci Lett 2010; 475: 64-68.
95. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009; 15: 6148-6157.
96. Bangert A, Hacker S, Cristofanon S, Debatin KM, Fulda S. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anticancer Drugs 2011; 22: 494-499.
97. Nor C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Childs Nerv Syst 2011; 27: 897-901.
98. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002; 22: 2965-2973. (Pubitemid 34437455)
99. Majello B, De Luca P, Hagen G, Suske G, Lania L. Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res 1994; 22: 4914-4921.
100. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J 1993; 12: 3551-3558. (Pubitemid 23256442)
101. Zeichner SL, Kim JY,Alwine JC. Linker-scanning mutational analysis of the transcrip-tional activity of the human immunodeficiency virus type 1 long terminal repeat J Virol 1991, 65. 2436-2444.
102. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 Tcells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-1108. (Pubitemid 38738509)
103. Choi BS, Lee HS, Oh YT, Hyun YL, Ro S, Kim SS et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS 2010; 24: 609-611.